Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease

Clinical Nephrology

Volumn 81, Issue 2, 2014, Pages 75-85

  Fassett, Robert G ^a   Robertson, Iain K ^b   Ball, Madeleine J ^b   Geraghty, Dominic P ^b   Coombes, Jeff S ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

CRP; IL 10; IL 6; IL 8; Inflammation; Pentraxin 3; Statins; TNF

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PENTRAXIN 3; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MARKER; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHRITIS; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; PYRROLES; RENAL INSUFFICIENCY, CHRONIC; TASMANIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893175308     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN108090     Document Type: Article

References (38)

1. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 1994; 45: 890-896. CrossRef PubMed
2. Knight EL, Rimm EB, Pai JK, Rexrode KM, Cannuscio CC, Manson JE, Stampfer MJ, Curhan GC. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol. 2004; 15: 1897-1903. CrossRef PubMed
3. Dubin R, Shlipak M, Li Y, Ix J, de Boer IH, Jenny N, Peralta CA. Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis. Nephrol Dial Transplant. 2011; 26: 1903-1908.PubMed.
4. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox). Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010; 77: 550-556. PubMed
5. Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, Chaves P, Furberg C, Kuller L, Newman A. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol. 2004; 15: 3184-3191. CrossRef PubMed
6. Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC. Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2009; 53: 596-605. CrossRef PubMed
7. Sarnak MJ, Poindexter A, Wang SR, Beck GJ, Kusek JW, Marcovina SM, Greene T, Levey AS. Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int. 2002; 62: 2208-2215. CrossRef PubMed
8. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004; 65: 1009-1016. CrossRef PubMed
9. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today. 1994; 15: 81-88. CrossRef PubMed
10. Gewurz H, Zhang XH, Lint TF. Structure and function of the pentraxins. Curr Opin Immunol. 1995; 7: 54-64. CrossRef PubMed
11. Nauta AJ, de Haij S, Bottazzi B, Mantovani A, Borrias MC, Aten J, Rastaldi MP, Daha MR, van Kooten C, Roos A. Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int. 2005; 67: 543-553. CrossRef PubMed
12. Bussolati B, Peri G, Salvidio G, Verzola D, Mantovani A, Camussi G. The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol. 2003; 170: 1466-1472. PubMed
13. Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimbürger O, Bárány P, Axelsson J, Alvestrand A, Stenvinkel P, Lindholm B, Suliman ME. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007; 2: 889-897. CrossRef PubMed
14. Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E, D'Auria F, Praderio L, Ciboddo G, Sabbadini MG, Manfredi AA, Mantovani A, Querini PR. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 2001; 44: 2841-2850. CrossRef PubMed
15. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, Maggioni AP, Moccetti T, Metra M, Cas LD, Ghezzi P, Sipe JD, Re G, Olivetti G, Mantovani A, Latini R. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000; 102: 636-641. CrossRef PubMed
16. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, Mantovani A. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001; 29: 1404-1407. CrossRef PubMed
17. Addabbo F, Mallamaci F, Leonardis D, Tripepi R, Tripepi G, Goligorsky MS, Zoccali C. Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrol Dial Transplant. 2007; 22: 3521-3526. CrossRef PubMed
18. Fox ER, Benjamin EJ, Sarpong DF, Nagarajarao H, Taylor JK, Steffes MW, Salahudeen AK, Flessner MF, Akylbekova EL, Fox CS, Garrison RJ, Taylor HA Jr. The relation of C-reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study. BMC Nephrol. 2010; 11: 1. CrossRef PubMed
19. Shankar A, Sun L, Klein BE, Lee KE, Muntner P, Nieto FJ, Tsai MY, Cruickshanks KJ, Schubert CR, Brazy PC, Coresh J, Klein R. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 2011; 80: 1231-1238. CrossRef PubMed
20. Guijarro C, Kim Y, Schoonover CM, Massy ZA, O'Donnell MP, Kasiske BL, Keane WF, Kashtan CE. Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant. 1996; 11: 990-996. CrossRef PubMed
21. Kim SY, Guijarro C, O'Donnell MP, Kasiske BL, Kim Y, Keane WF. Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. Kidney Int. 1995; 48: 363-371. CrossRef PubMed
22. Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O'Donnell MP. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun. 2000; 267: 536-540. CrossRef PubMed
23. O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest. 1993; 91: 83-87. CrossRef PubMed
24. Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int. 1993; 43: 218-225. CrossRef PubMed
25. Panichi V, Paoletti S, Mantuano E, Manca-Rizza G, Filippi C, Santi S, Taccola D, Donadio C, Tramonti G, Innocenti M, Casto G, Consani C, Sbragia G, Franzoni F, Galetta F, Panicucci E, Barsotti G. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant. 2006; 21: 337-344. CrossRef PubMed
26. Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gómez-Campderá F, Vega A, Abad S, Luño J. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17 (Suppl 3): S231-S235. CrossRef PubMed
27. Dummer CD, Thome' FS, Zingano B, Lindoso A, Veronese FV. Acute effect of simvastatin on inflammation and oxidative stress in chronic kidney disease. J Nephrol. 2008; 21: 900-908. PubMed
28. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006; 17: 2006-2016. CrossRef PubMed
29. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008; 336: 645-651. CrossRef PubMed
30. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001; 59: 260-269. CrossRef PubMed
31. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B et al; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377: 2181-2192. CrossRef PubMed
32. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; CORONA Study Group. Effects of statin therapy accord ing to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation. 2009; 120: 2188-2196. CrossRef PubMed
33. Jonathan Emberson, Derrick Bennett, Emma Link, Sarah Parish, John Danesh, Jane Armitage, Rory Collins; Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011; 377: 469-476. CrossRef PubMed
34. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005; 68: 237-245. CrossRef PubMed
35. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis. 2010; 213: 218-224. PubMed
36. Fassett RG, Ball MJ, Robertson IK, Geraghty DP, Coombes JS. The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol. 2008; 9: 4. CrossRef PubMed
37. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53: 766-772. CrossRef PubMed
38. McDonald SCS, Excell L. ANZDATA Registry 2006 Report. 2007. http://www.anzdata.org.au/ anzdata/AnzdataReport/30thReport/Ch02NewPatients. pdf.